[b]Hospira[/b] has successfully overturned two patents on [b]Roche’s[/b] breast cancer drug [b]Herceptin[/b] in Britain, clearing the way for a cheaper copycat version in that country. [s]Reuters Health[/s] reports that this would ramp up competition for a costly cancer treatment and could drive down prices. The potential to use copycat forms of biotech drugs like Herceptin is gaining increased attention from cost-conscious health authorities across Europe.
[link url=http://www.reuters.com/article/2014/04/10/us-roche-hldg-hospira-idUSBREA3916H20140410] Full Reuters Health report[/link]